Abstract
Cefaclor, a new cephalosporin, was orally administered to 39 cases in oral infections and the daily dose was ranged 750mg.
The following results were obtained from 20 cases, but from 37 cases for the adverse effect.
1) The overall clinical effective rate of cefaclor was 70.0%.
2) No adverse effect was recognized in clinical findings except a slight high value of BUN in blood examination.
3) Bacteriologically, 30 strains were isolated from 22 cases (59.5% of 37 cases) .
4) Three resistant strains and a high resistant strain (Flavobacteriuyn) were observed.
5) Cefaclor showed higher antibacterial activity against isolated strains than CEX, but inferior to ABPC or AMPC.
Summarizing the above results, cefaclor is considered effective for the oral infections.
